on ABIONYX (EPA:ABNX)
ABIONYX Pharma in talks for a strategic partnership in sepsis
ABIONYX Pharma, a biotechnology company specializing in innovative therapies, announced on August 27, 2025, the opening of discussions with a major player in the healthcare sector on sepsis. This proposed collaboration aims to accelerate the development and deployment of CER-001, a potential treatment for sepsis.
This partner, recognized for its influence in the sector, is exploring the possibilities of a strategic alliance with ABIONYX to benefit from its cutting-edge technology. These discussions mark an important milestone for the company, highlighting the growing interest in its technological approach to the treatment of sepsis.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIONYX news